Towards Better Delivery of Cannabidiol (CBD)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/9/219 |
| _version_ | 1797555208475115520 |
|---|---|
| author | Sophie Anne Millar Ryan Francis Maguire Andrew Stephen Yates Saoirse Elizabeth O’Sullivan |
| author_facet | Sophie Anne Millar Ryan Francis Maguire Andrew Stephen Yates Saoirse Elizabeth O’Sullivan |
| author_sort | Sophie Anne Millar |
| collection | DOAJ |
| description | Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent. |
| first_indexed | 2024-03-10T16:44:14Z |
| format | Article |
| id | doaj.art-c232b18773a94e3fbad4c4040432062b |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T16:44:14Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-c232b18773a94e3fbad4c4040432062b2023-11-20T11:47:01ZengMDPI AGPharmaceuticals1424-82472020-08-0113921910.3390/ph13090219Towards Better Delivery of Cannabidiol (CBD)Sophie Anne Millar0Ryan Francis Maguire1Andrew Stephen Yates2Saoirse Elizabeth O’Sullivan3Artelo Biosciences, 888 Prospect Street, Suite 210, La Jolla, CA 92037, USADivision of Graduate Entry Medicine and Medical Sciences, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UKArtelo Biosciences, 888 Prospect Street, Suite 210, La Jolla, CA 92037, USAArtelo Biosciences, 888 Prospect Street, Suite 210, La Jolla, CA 92037, USACannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.https://www.mdpi.com/1424-8247/13/9/219cannabidiolCBDformulationclinical development |
| spellingShingle | Sophie Anne Millar Ryan Francis Maguire Andrew Stephen Yates Saoirse Elizabeth O’Sullivan Towards Better Delivery of Cannabidiol (CBD) Pharmaceuticals cannabidiol CBD formulation clinical development |
| title | Towards Better Delivery of Cannabidiol (CBD) |
| title_full | Towards Better Delivery of Cannabidiol (CBD) |
| title_fullStr | Towards Better Delivery of Cannabidiol (CBD) |
| title_full_unstemmed | Towards Better Delivery of Cannabidiol (CBD) |
| title_short | Towards Better Delivery of Cannabidiol (CBD) |
| title_sort | towards better delivery of cannabidiol cbd |
| topic | cannabidiol CBD formulation clinical development |
| url | https://www.mdpi.com/1424-8247/13/9/219 |
| work_keys_str_mv | AT sophieannemillar towardsbetterdeliveryofcannabidiolcbd AT ryanfrancismaguire towardsbetterdeliveryofcannabidiolcbd AT andrewstephenyates towardsbetterdeliveryofcannabidiolcbd AT saoirseelizabethosullivan towardsbetterdeliveryofcannabidiolcbd |